Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. (avaa uuden ikkunan)

CRASH-3 Trial Collaborators

Lähde‎: Lancet 2019;394(10210):1713-23.

Arkistoitu‎: PubMed 31623894

DOI‎: 10.1016/S0140-6736(19)32233-0

https://www.ncbi.nlm.nih.gov/pubmed/31623894 (avaa uuden ikkunan)

Alternatives to allogeneic platelet transfusion. (avaa uuden ikkunan)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Lähde‎: Br J Haematol 2016;175(3):381-92.

Arkistoitu‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (avaa uuden ikkunan)

Tranexamic acid: less bleeding and less thrombosis? (avaa uuden ikkunan)

Godier A, Roberts I, Hunt BJ.

Lähde‎: Crit Care 2012;16(3):135.

Arkistoitu‎: PubMed 22748073

DOI‎: 10.1186/cc11374

https://www.ncbi.nlm.nih.gov/pubmed/22748073 (avaa uuden ikkunan)

Tranexamic acid for reducing mortality in emergency and urgent surgery. (avaa uuden ikkunan)

Perel P, Ker K, Morales Uribe CH, Roberts I

Lähde‎: Cochrane Database Syst Rev 2013;(1):CD010245.

Arkistoitu‎: PubMed 23440847

DOI‎: 10.1002/14651858.CD010245.pub2

https://www.ncbi.nlm.nih.gov/pubmed/23440847 (avaa uuden ikkunan)

The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. (avaa uuden ikkunan)

Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T; CRASH-2 collaborators.

Lähde‎: Lancet 2011;377(9771):1096-101, 1101.e1-2.

Arkistoitu‎: PubMed 21439633

DOI‎: 10.1016/S0140-6736(11)60278-X

https://www.ncbi.nlm.nih.gov/pubmed/21439633 (avaa uuden ikkunan)

Antifibrinolytic drugs for acute traumatic injury. (avaa uuden ikkunan)

Roberts I, Shakur H, Ker K, Coats T; CRASH‐2 Trial collaborators.

Lähde‎: Cochrane Database Syst Rev 2011;(1):CD004896.

Arkistoitu‎: PubMed 21249666

DOI‎: 10.1002/14651858.CD004896.pub3

https://www.ncbi.nlm.nih.gov/pubmed/21249666 (avaa uuden ikkunan)

Use of tranexamic acid to reduce bleeding in burns surgery. (avaa uuden ikkunan)

Tang YM, Chapman TW, Brooks P

Lähde‎: J Plast Reconstr Aesthet Surg 2012;65(5):684-6.

Arkistoitu‎: PubMed 21983540

DOI‎: 10.1016/j.bjps.2011.09.028

https://www.ncbi.nlm.nih.gov/pubmed/21983540 (avaa uuden ikkunan)

Tranexamic acid reduced blood transfusions in acute burn surgery: a retrospective case-controlled trial. (avaa uuden ikkunan)

Tapking C, Hundeshagen G, Kirchner M, Fischer S, Kneser U, Bliesener B

Lähde‎: Burns. 2022;48(3):522-28.

Arkistoitu‎: PubMed 35339324

DOI‎: 10.1016/j.burns.2022.03.002

https://pubmed.ncbi.nlm.nih.gov/35339324/ (avaa uuden ikkunan)

Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery. (avaa uuden ikkunan)

Barua A, Rao VP, Ramesh B, Barua B, El-Shafei H.

Lähde‎: J Blood Med 2011;2:131-4.

Arkistoitu‎: PubMed 22287872

DOI‎: 10.2147/JBM.S21609

https://www.ncbi.nlm.nih.gov/pubmed/22287872 (avaa uuden ikkunan)

The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. (avaa uuden ikkunan)

Boffard KD, Choong PI, Kluger Y, Riou B, Rizoli SB, Rossaint R, Warren B; NovoSeven Trauma Study Group.

Lähde‎: Transfusion 2009;49 Suppl 5:240S-7S.

Arkistoitu‎: PubMed 19954486

DOI‎: 10.1111/j.1537-2995.2008.01987.x

https://www.ncbi.nlm.nih.gov/pubmed/19954486 (avaa uuden ikkunan)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (avaa uuden ikkunan)

Fries D

Lähde‎: Transfusion 2013;53 Suppl 1:91S-5S.

Arkistoitu‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (avaa uuden ikkunan)

A Jehovah's Witness with complex abdominal trauma and coagulopathy: use of factor VII and a review of the literature. (avaa uuden ikkunan)

Haan J, Scalea T

Lähde‎: Am Surg 2005;71(5):414-5.

Arkistoitu‎: PubMed 15986972

https://www.ncbi.nlm.nih.gov/pubmed/15986972 (avaa uuden ikkunan)

Results of the control trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. (avaa uuden ikkunan)

Hauser CJ, Boffard K, Dutton R, Bernard GR, Croce MA, Holcomb JB, Leppaniemi A, Parr M, Vincent JL, Tortella BJ, Dimsits J, Bouillon B; CONTROL Study Group.

Lähde‎: J Trauma 2010;69(3):489-500.

Arkistoitu‎: PubMed 20838118

DOI‎: 10.1097/TA.0b013e3181edf36e

https://www.ncbi.nlm.nih.gov/pubmed/20838118 (avaa uuden ikkunan)

Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. (avaa uuden ikkunan)

Hsia CC, Chin-Yee IH, McAlister VC.

Lähde‎: Ann Surg 2008;248(1):61-8.

Arkistoitu‎: PubMed 18580208

DOI‎: 10.1097/SLA.0b013e318176c4ec

https://www.ncbi.nlm.nih.gov/pubmed/18580208 (avaa uuden ikkunan)

Rescue treatment with recombinant factor VIIa is effective in patients with life-threatening bleedings secondary to major wound excision: a report of four cases. (avaa uuden ikkunan)

Johansson PI, Eriksen K, Alsbjørn B

Lähde‎: J Trauma 2006;61(4):1016-8.

Arkistoitu‎: PubMed 17033583

DOI‎: 10.1097/01.ta.0000239261.48022.f1

https://www.ncbi.nlm.nih.gov/pubmed/17033583 (avaa uuden ikkunan)

Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding. (avaa uuden ikkunan)

Kandane-Rathnayake RK, Isbister JP, Zatta AJ, Aoki NJ, Cameron P, Phillips LE; Australian and New Zealand Haemostasis Registry Steering Committee

Lähde‎: ANZ J Surg 2013;83(3):155-60.

Arkistoitu‎: PubMed 23035873

DOI‎: 10.1111/j.1445-2197.2012.06285.x

https://www.ncbi.nlm.nih.gov/pubmed/23035873 (avaa uuden ikkunan)

Recombinant factor VIIa in trauma patients with the 'triad of death.' (avaa uuden ikkunan)

Mitra B, Cameron PA, Parr MJ, Phillips L.

Lähde‎: Injury 2012;43(9):1409-14.

Arkistoitu‎: PubMed 21345431

DOI‎: 10.1016/j.injury.2011.01.033

https://www.ncbi.nlm.nih.gov/pubmed/21345431 (avaa uuden ikkunan)

Low-dose recombinant factor VIIa for trauma patients with coagulopathy. (avaa uuden ikkunan)

Stein DM, Dutton RP, Hess JR, Scalea TM.

Lähde‎: Injury 2008;39(9):1054-61.

Arkistoitu‎: PubMed 18656871

DOI‎: 10.1016/j.injury.2008.03.032

https://www.ncbi.nlm.nih.gov/pubmed/18656871 (avaa uuden ikkunan)

Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (Novoseven®). (avaa uuden ikkunan)

Tanaka KA, Waly AA, Cooper WA, Levy JH.

Lähde‎: Anesthesiology 2003;98(6):1513-5.

Arkistoitu‎: PubMed 12766668

https://www.ncbi.nlm.nih.gov/pubmed/12766668 (avaa uuden ikkunan)

Alternatives to allogeneic platelet transfusion. (avaa uuden ikkunan)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Lähde‎: Br J Haematol 2016;175(3):381-92.

Arkistoitu‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (avaa uuden ikkunan)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (avaa uuden ikkunan)

Fries D

Lähde‎: Transfusion 2013;53 Suppl 1:91S-5S.

Arkistoitu‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (avaa uuden ikkunan)

Plasma fibrinogen level on admission to the intensive care unit is a powerful predictor of postoperative bleeding after cardiac surgery with cardiopulmonary bypass. (avaa uuden ikkunan)

Kindo M, Hoang Minh T, Gerelli S, Perrier S, Meyer N, Schaeffer M, Bentz J, Announe T, Mommerot A, Collange O, Pottecher J, Cristinar M, Thiranos JC, Gros H, Mertes PM, Billaud P, Mazzucotelli JP

Lähde‎: Thromb Res 2014;134(2):360-8.

Arkistoitu‎: PubMed 24857189

DOI‎: 10.1016/j.thromres.2014.05.008

https://www.ncbi.nlm.nih.gov/pubmed/24857189 (avaa uuden ikkunan)

Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. (avaa uuden ikkunan)

Larsen OH, Stentoft J, Radia D, Ingerslev J, Sørensen B

Lähde‎: Br J Haematol 2013;160(2):228-36.

Arkistoitu‎: PubMed 23151086

DOI‎: 10.1111/bjh.12118

https://www.ncbi.nlm.nih.gov/pubmed/23151086 (avaa uuden ikkunan)

Strategies to reduce the use of blood products: a European perspective. (avaa uuden ikkunan)

Theusinger OM, Felix C, Spahn DR.

Lähde‎: Curr Opin Anaesthesiol 2012;25(1):59-65.

Arkistoitu‎: PubMed 22113184

DOI‎: 10.1097/ACO.0b013e32834dec98

https://www.ncbi.nlm.nih.gov/pubmed/22113184 (avaa uuden ikkunan)

Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. (avaa uuden ikkunan)

Crescenzi G, Landoni G, Biondi-Zoccai G, Pappalardo F, Nuzzi M, Bignami E, Fochi O, Maj G, Calabrò MG, Ranucci M, Zangrillo A

Lähde‎: Anesthesiology 2008;109(6):1063-76.

Arkistoitu‎: PubMed 19034103

DOI‎: 10.1097/ALN.0b013e31818db18b

https://www.ncbi.nlm.nih.gov/pubmed/19034103 (avaa uuden ikkunan)

Alternatives to allogeneic platelet transfusion. (avaa uuden ikkunan)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Lähde‎: Br J Haematol 2016;175(3):381-92.

Arkistoitu‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (avaa uuden ikkunan)

Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. (avaa uuden ikkunan)

Svensson PJ, Bergqvist PB, Juul KV, Berntorp E

Lähde‎: Blood Rev 2014;28(3):95-102.

Arkistoitu‎: PubMed 24703870

DOI‎: 10.1016/j.blre.2014.03.001

https://www.ncbi.nlm.nih.gov/pubmed/24703870 (avaa uuden ikkunan)

Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients. (avaa uuden ikkunan)

Alperin JB

Lähde‎: JAMA 1987;258(14):1916-9.

Arkistoitu‎: PubMed 3656602

DOI‎: 10.1001/jama.1987.03400140078028

https://www.ncbi.nlm.nih.gov/pubmed/3656602 (avaa uuden ikkunan)

Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study. (avaa uuden ikkunan)

Crowther MA, McDonald E, Johnston M, Cook D

Lähde‎: Blood Coagul Fibrinolysis 2002;13(1):49-52.

Arkistoitu‎: PubMed 11994567

DOI‎: 10.1097/00001721-200201000-00007

https://www.ncbi.nlm.nih.gov/pubmed/11994567 (avaa uuden ikkunan)

The use of fibrin sealant in burn operations. (avaa uuden ikkunan)

Foster K

Lähde‎: Surgery 2007;142(4 Suppl):S50-4.

Arkistoitu‎: PubMed 18019939

DOI‎: 10.1016/j.surg.2007.06.026

https://www.ncbi.nlm.nih.gov/pubmed/18019939 (avaa uuden ikkunan)

Use of fibrin sealant in thermal injury. (avaa uuden ikkunan)

McGill V, Kowal-Vern A, Lee M, Greenhalgh D, Gomperts E, Bray G, Gamelli R

Lähde‎: J Burn Care Rehabil 1997;18(5):429-34.

Arkistoitu‎: PubMed 9313125

DOI‎: 10.1097/00004630-199709000-00011

https://www.ncbi.nlm.nih.gov/pubmed/9313125 (avaa uuden ikkunan)

Perioperative treatment algorithm for bleeding burn patients reduces allogeneic blood product requirements. (avaa uuden ikkunan)

Schaden E, Kimberger O, Kraincuk P, Baron DM, Metnitz PG, Kozek-Langenecker S

Lähde‎: Br J Anaesth 2012;109(3):376-81.

Arkistoitu‎: PubMed 22719014

DOI‎: 10.1093/bja/aes186

https://www.ncbi.nlm.nih.gov/pubmed/22719014 (avaa uuden ikkunan)

Transfusion in trauma: why and how should we change our current practice? (avaa uuden ikkunan)

Theusinger OM, Spahn DR, Ganter MT.

Lähde‎: Curr Opin Anaesthesiol 2009;22(2):305-12.

Arkistoitu‎: PubMed 19390257

DOI‎: 10.1097/ACO.0b013e3283212c7c

https://www.ncbi.nlm.nih.gov/pubmed/19390257 (avaa uuden ikkunan)

Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. (avaa uuden ikkunan)

Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, Misso K, Ross J, Severens J, Kleijnen J

Lähde‎: Health Technol Assess 2015;19(58):1-228.

Arkistoitu‎: PubMed 26215747

DOI‎: 10.3310/hta19580

https://www.ncbi.nlm.nih.gov/pubmed/26215747 (avaa uuden ikkunan)